Anti-Complement C9 Antibody (C9 53)
Our mouse Complement C9 monoclonal antibody from Antibodies Incorporated is produced in-house from clone C9 53. It detects human Complement C9 and is Protein A or Protein G purified. Works in ELISA.
SKU: ABS 004-53-010
Ships: 1-2 business days
Product Details
Complement C9
Complement factor C9 is a 71 kDa single-chain ellipsoid a-globular molecule of 558 amino acids including a leader sequence of 20 amino acids. C9 bind the C5b8 complex on membranes and has an unique property in forming tubular structures containing between 12 and 18 monomers, closely resembling the membrane attack complex (MAC). The primary site of synthesis is hepatocytes, secondary sites are monocytes, fibroblasts and glial cells. The normal level of C9 in plasma is 60 µg/mL, and the level is up regulated from hepatocytes by IFN-ɣ.
Protein A or Protein G purified
1 mg/mL ±15%
Monoclonal
C9 53
IgG1/k
ELISA
Mouse
C9
71 kDa
Complement factor C9
Human
Human
2-8°C without exposure to light
Liquid
BSA free
0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
ELISA: 1:50
ABS 004-53 recognizes C9 in human serum diluted 1/50 in Tris buffer (20 mM Tris-base, 1 mM MgCl2, 1 mM CaCl2 and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 µg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour) ELISA plate.
Unconjugated
ABS 004-53 is specific for complement factor C9.
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.
United States
24 months from date of receipt
Complement component C9; Cleaved into: Complement component C9a; Complement component C9b; ARMD15; C9D; complement component 9; C9
Pore-forming component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:22832194, PubMed:26841837, PubMed:26841934, PubMed:27052168, PubMed:30552328, PubMed:6177822, PubMed:9212048, PubMed:9634479). The MAC is initiated by proteolytic cleavage of C5 into complement C5b in response to the classical, alternative, lectin and GZMK complement pathways (PubMed:39914456, PubMed:39814882, PubMed:9212048, PubMed:9634479). The complement pathways consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:9212048, PubMed:9634479). Constitutes the pore-forming subunit of the MAC complex: during MAC assembly, C9 associates with the C5b8 intermediate complex, and polymerizes to complete the pore (PubMed:26841934, PubMed:30111885, PubMed:30552328, PubMed:34752492, PubMed:4055801, PubMed:6177822). {ECO:0000269|PubMed:22832194, ECO:0000269|PubMed:26841837, ECO:0000269|PubMed:26841934, ECO:0000269|PubMed:27052168, ECO:0000269|PubMed:30111885, ECO:0000269|PubMed:30552328, ECO:0000269|PubMed:34752492, ECO:0000269|PubMed:39814882, ECO:0000269|PubMed:39914456, ECO:0000269|PubMed:4055801, ECO:0000269|PubMed:6177822, ECO:0000269|PubMed:9212048, ECO:0000269|PubMed:9634479}.
735
Shipped on ice packs

